PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen

Modern Pathology

Volumn 16, Issue 5, 2003, Pages 481-490

  Rochaix, Philippe ^a,c   Lacroix Triki, Magali ^a   Lamant, Laurence ^b   Pichereaux, Carole ^d   Valmary, Severine ^b   Puente, Elena ^c   Al Saati, Talal ^b   Monsarrat, Bernard ^d   Susini, Christiane ^c   Buscail, Louis ^c   Delsol, Georges ^b   Voigt, Jean Jacques ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b France   (France)

^c INSERM   (France)

^d INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Clathrin 17; Immunohistochemistry; Melanoma; Monoclonal antibody; Pre albumin, Proteomic; TAP1

Indexed keywords

CELL ANTIGEN; CLATHRIN; FIXATIVE; GLYCOPROTEIN GP 100; MELAN A; MELANIN; MELANOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMB 45; MONOCLONAL ANTIBODY PNL2; PREALBUMIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ANGIOMYOLIPOMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CLEAR CELL SARCOMA; CONTROLLED STUDY; GRANULOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LENTIGO; LYMPHANGIOLEIOMYOMATOSIS; MASS SPECTROMETRY; MELANOCYTE; MELANOMA; METASTASIS; MOUSE; MOUTH MUCOSA; NEVUS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SKIN CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS; CELL LINE, TUMOR; DRUG RESISTANCE; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; MICE; MICE, INBRED BALB C; PROTEOMICS; SKIN NEOPLASMS; TISSUE DISTRIBUTION; TISSUE FIXATION;

EID: 0038146919     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000067686.34489.50     Document Type: Article

References (42)

1. Lodding P, Kindblom LG, Angervall L. Metastases of malignant melanoma simulating soft tissue sarcoma. A clinico-pathological, light- and electron microscopic and immunohistochemical study of 21 cases. Virchows Arch A Pathol Anat Histopathol 1990;417:377-88.
2. Fetsch PA, Fetsch JF, Marincola FM, Travis W, Batts KP, Abati A. Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. Mod Pathol 1998;11:699-703.
3. Adema GJ, Bakker AB, de Boer AJ, Hohenstein P, Figdor CG. pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL. Br J Cancer 1996;73:1044-8.
4. Adema GJ, de Boer AJ, van't Hullenaar R, Denijn M, Ruiter DJ, Vogel AM, et al. Melanocyte lineage- specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 1993;143:1579-85.
5. Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998;22:976-82.
6. Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 2000;13:459-65.
7. Busam KJ, Iversen K, Coplan KA, Old LJ, Stockert E, Chen YT, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol 1998;22:57-63.
8. Cohen-Knafo E, al Saati T, Aziza J, Ralfkiaer E, Selves J, Gorguet B, et al. Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections. J Clin Pathol 1995;48:826-31.
9. Fetsch PA, Cormier J, Hijazi YM. Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. J Immunother 1997;20:60-4.
10. Fetsch PA, Marincola FM, Abati A. The new melanoma markers: MART-1 and Melan-A. Am J Surg Pathol 1999;23:607-10.
11. Gudat F, Zuber M, Durmuller U, Kocher T, Schaefer C, Noppen C, et al. The tumour-associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchows Arch 1996;429:77-81.
12. Hofbauer GF, Kamarashev J, Geertsen R, Boni R, Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin- embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res 1998;8:337-43.
13. Hofbauer GF, Schaefer C, Noppen C, Boni R, Kamarashev J, Nestle FO, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997;151:1549-53.
14. Jungbluth AA, Busam KJ, Gerald WL, Stockert E, Coplan KA, Iversen K, et al. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol 1998;22:595-602.
15. Kaufmann O, Koch S, Burghardt J, Audring H, Dietel M. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol 1998;11:740-6.
16. Lazzaro B, Strassburg A. Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies. Hybridoma 1996;15:141-6.
17. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer 1999;85:2391-9.
18. Biesterfeld S, Kusche M, Viereck E, Fuzesi L. Limited value of the NKI/C3-antibody for the differential diagnosis of Paget's disease of the nipple and intra-epidermal malignant melanoma. Histopathology 1996;28:269-70.
19. Pernick NL, DaSilva M, Gangi M.D., Crissman J, Adsay V. "Histiocytic markers" in melanoma. Mod Pathol 1999;12:1072-7.
20. Brinckerhoff LH, Thompson LW, Slingluff CL Jr. Melanoma vaccines. Curr Opin Oncol 2000;12:163-73.
21. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000 1;86:385-92.
22. Mitchell MS. Cancer vaccines, a critical review - Part I. Curr Opin Investig Drugs 2002;3:140-9.
23. Mitchell MS. Cancer vaccines, a critical review - Part II. Curr Opin Investig Drugs 2002;3:150-8.
24. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, et al. Cancer immunotherapy with peptidebased vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805-18.
25. Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000;23:59-66.
26. Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 2000;23:275-81.
27. Sun Y, Paschen A, Schadendorf D. Cell-based vaccination against melanoma-background, preliminary results, and perspective. J Mol Med 1999;77:593-608.
28. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with MAGE-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999 6;190:1669-78.
29. Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 2000 15;164:1125-31.
30. Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999 15;198:131-8.
31. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-65.
32. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999;22:431-40.
33. al Saati T, Clamens S, Cohen-Knafo E, Faye JC, Prats H, Coindre JM, et al. Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer 1993 21;55:651-4.
34. Harlow E, Lane D. Antibodies: a laboratory manual. New York: Cold Spring Harbor Laboratory; 1988.
35. Raymond I, Al Saati T, Tkaczuk J, Chittal S, Delsol G. CNA.42, a new monoclonal antibody directed against a fixative-resistant antigen of follicular dendritic reticulum cells. Am J Pathol 1997;151:1577-85.
36. Mann M, Hendrickson R, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem 2001; 70:437-73.
37. Clover LM, Sargent IL, Townsend A, Tampe R, Redman CW. Expression of TAP1 by human trophoblast. Eur J Immunol 1995;25:543-53.
38. Clover LM, Coghill E, Redman CW, Sargent IL. A three-colour flow cytometry technique for measuring trophoblast intracellular antigens: the relative expression of TAP1 in human cytotrophoblast and decidual cells. Placenta 2000;21:743-53.
39. Kishore R, Hicklin DJ, Dellaratta DV, Golde U, Kageshita T, Seliger B, et al. Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. Tissue Antigens 1998;51:129-40.
40. Matsui M, Ikeda M, Akatsuka T. High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation. Biochem Biophys Res Commun 2001;280:1008-14.
41. Palmisano GL, Pistillo MP, Capanni P, Pera C, Nicolo G, Salvi S, et al. Investigation of HLA class I downregulation in breast cancer by RT-PCR. Hum Immunol 2001;62:133-9.
42. al Saati T, Caspar S, Brousset P, Chittal S, Caveriviere P, Hounieu H, et al. Production of anti-B monoclonal antibodies (DBB.42, DBA.44, DNA.7, and DND.53) reactive on paraffin- embedded tissues with a new B-lymphoma cell line grafted into athymic nude mice. Blood 1989;74:2476-85.